FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Moving Ahead with Unique Device Identifier

[ Price : $8.95]

CDRH director Dan Schultz tells RAPS the agency intends to establish a unique device identifier system for medical devices to redu...

Measuring Compliance: Issue Shows Need for FDA Lab

[ Price : $8.95]

Consulting editor John Scharmann follows up on responses to his article of measuring compliance, observing that the situation warr...

Terrorism Duties Take More CBER Reviewers

[ Price : $8.95]

CBER director Jesse Goodman says current concerns over terrorism, including bioterrorism, are increasingly occupying the Centers r...

CDERs Jenkins Says Honesty is Most Important in NDAs

[ Price : $8.95]

Asked to provide his best advice for industry in their dealings with the agency, CDER Office of New Drugs director says be honest ...

Device Inspections Scrutinize Corrections and Removals

[ Price : $8.95]

CDRH special assistant Casper Uldriks says FDA investigators are closely examining medical device Corrections and Removals reporti...

Fixed Dose Combo HIV Drug Guidance Out

[ Price : $8.95]

FDA issues a guidance for sponsors submitting applications for HIV fixed dose combination therapies.

New Type of Diabetes Treatment Approved

[ Price : $8.95]

FDA approves Mercks Januvia for treating Type 2 diabetes alone or with two other common diabetes drugs.

Qiagen Reagents Have Not Been Approved

[ Price : $8.95]

FDA says Qiagen GmbH does not have an approved PMA for ASRs it is marketing directly to clinical laboratories.

Crawfords Fall Emblematic of a Wider Decay

[ Price : $8.95]

FDA Webview editor James G. Dickinson says the Crawford plea bargain makes the former commissioner emblematic of a wider decay in ...

FDA Debars Butkovitz

[ Price : $8.95]

Federal Register Notice: FDA issues an order permanently debarring Anne L. Butkovitz from providing services to a person with a pe...